Cobenfy, the novel antipsychotic drug that Bristol Myers Squibb obtained from a $14 billion acquisition, could have a problem. The drug recently failed as an adjunctive treatment in a phase 3 ...

Sky-high sales prospects for Bristol Myers Squibb's new schizophrenia treatment Cobenfy may have to be scaled down after a trial designed to expand the label of the recently approved drug failed ...

Scientists have discovered novel drug candidates that could ultimately lead to new effective treatments for conditions caused ...

Bristol Myers Squibb is undervalued despite challenges. Learn how BMY stock's strong pipeline, cash flow, and growth ...

Cobenfy is also in phase 3 clinical testing as an add-on to existing drugs for schizophrenia and the treatment of psychosis in patients with Alzheimer's disease and in phase 2 for bipolar disorder ...

Shares of this biotech giant have lost 16.3% year to date compared with the industry’s decline of 2.7%. The sto ...

Scientists have discovered novel drug candidates which could ultimately lead to new effective treatments for conditions ...

Bristol-Myers Squibb faces revenue declines but offers long-term potential via growth drugs. Read what BMY stock has to offer ...

Medically reviewed by Michael MacIntyre, MDSchizophrenia medication falls under two main categories: older, first-generation, or "typical" antipsychotics and newer drugs for schizophrenia known as ...

AbbVie, Inc. ABBV and Bristol Myers Squibb BMY are leading drugmakers with broad and diverse portfolios and a global footprint. AbbVie is a global, diversified biopharmaceutical company with a ...

Cobenfy represents the first new pharmacological approach to treating schizophrenia in decades. This drug is expected to contribute meaningfully to BMY’s top line in the coming years.